Roche Under Fire Over ‘Unaffordable’ COVID-19 Therapy Actemra
The WHO Calls For Lower Prices
The World Health Organization has taken the unusual step of calling for lower drug prices to help patient access IL-6 therapies in developing nations.
You may also be interested in...
In this week's podcast edition of Five Must-Know Things: Novartis’s US strategy for inclisiran; Roche under pressure over prices for Actemra in COVID; Lambda coronavirus variant poses new challenge for vaccines; GSK loses its oncology R&D head; and a look at expected Q3 approvals in the US.
The RECOVERY trial has found Actemra to help cut deaths and speed recovery – and UK doctors are not waiting for Roche to complete own studies.
Brexpiprazole could be approved as soon as 2023, and Lundbeck has pledged to support its uptake with investment in its salesforce and direct-to-consumer advertising.